Kymera Therapeutics stock gains as Stifel lifts its target

Published on 09/22/2026 at 15:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kymera Therapeutics stock traded at USD 117.67 on September 22, 2026, as Stifel raised its target by 29 percent. Market value reached USD 9.78 billion.

KYMR, US50153V1061, Illustration mit AI erstellt.

Kymera Therapeutics, Inc. (US50153V1061) traded at USD 117.67 on the Nasdaq on September 22, 2026, while Stifel raised its price target and linked the change to the company's clinical-trial outlook. The valuation signal is clear: market capitalization stood at USD 9.78 billion on September 22, 2026.

Stifel raises the valuation bar

According to Investing.com on September 22, 2026, Stifel increased its Kymera price target, with the new target implying roughly 29 percent upside from the reported USD 117.67 share price. The report identified the drug trial outlook as the reason for the revised view.

That comparison gives the current quotation a concrete benchmark, but it is not a guarantee of performance. Investing.com also reported that InvestingPro data considered the stock overvalued relative to its fair-value estimate on September 22, 2026, creating a counter-factor alongside the higher analyst target.

Market value reaches USD 9.78 billion

MarketBeat reported on September 22, 2026, that Kymera had a market capitalization of USD 9.78 billion and a price-to-earnings ratio of negative 36.32. The negative ratio reflects a loss-making earnings base, so the investment case depends more heavily on clinical progress and future commercial potential than on current earnings.

A separate market snapshot identified Kymera Therapeutics at USD 117.93, up 0.15 percent, with market capitalization of USD 9.701 billion on September 21, 2026. The difference between the USD 117.67 and USD 117.93 quotations reflects different timestamps or market-data snapshots, so the article uses the September 22 quotation as its single reference price.

Clinical outlook meets earnings risk

The central tension is numerical: a target implying 29 percent upside sits beside a negative 36.32 price-to-earnings ratio and a multibillion-dollar valuation. For investors, the next decisive evidence is therefore likely to come from trial execution and reported operating figures rather than from the current earnings multiple alone.

Kymera Therapeutics stock closed at USD 117.67 on the Nasdaq on September 22, 2026. The same date's market capitalization was USD 9.78 billion, while the Stifel target update implied approximately 29 percent upside from that quotation.